(English) Catalent Gene Therapy Facility Receives FDA Approval as an Additional Manufacturing Site for AveXis’ Gene Therapy

SOMERSET, N.J., Aug. 6, 2020 /PRNewswire-PRWeb/ — Catalent, the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health products, today announced that it was approved by the U.S. Food and Drug Administration (FDA) to produce commercial drug substance intermediate for AveXis’ spinal muscular atrophy (SMA) gene therapy at its manufacturing facility located in Harmans,…